Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9NZP8
UPID:
C1RL_HUMAN
Alternative names:
C1r-like serine protease analog protein
Alternative UPACC:
Q9NZP8; Q53GX9
Background:
The Complement C1r subcomponent-like protein, also known as C1r-like serine protease analog protein, plays a crucial role in the proteolytic cleavage of HP/haptoglobin within the endoplasmic reticulum. This protein's unique function highlights its importance in the proteolytic process, essential for maintaining cellular homeostasis.
Therapeutic significance:
Understanding the role of Complement C1r subcomponent-like protein could open doors to potential therapeutic strategies. Its pivotal role in proteolytic cleavage presents an opportunity for developing targeted treatments that could modulate this protein's activity for therapeutic benefits.